Inspira Technologies Targets Mechanical Ventilation Market

Inspira Technologies Oxy BHN (IINN) has released an update.

Inspira Technologies Oxy BHN Ltd. announced aggressive promotion plans for its ART100 device in the U.S. and other markets, following FDA clearance. The company aims to capture a share of the $19 billion mechanical ventilation market with its next-gen INSPIRA ART (Gen 2) technology, designed to oxygenate blood directly, potentially without intubation. Inspira also highlighted its strategic milestones including multi-site deployment of ART100 and advancement of its HYLA blood sensor and VORTX blood delivery system.

For further insights into IINN stock, check out TipRanks’ Stock Analysis page.